Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s Why

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $9.61, but opened at $9.19. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.2050, with a volume of 10,709 shares traded.

Analyst Upgrades and Downgrades

SGIOY has been the topic of several recent research reports. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. Zacks Research lowered Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 16th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Shionogi & Co., Ltd. Unsponsored ADR has a consensus rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 3.1%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.21 and a current ratio of 5.84. The firm has a market capitalization of $15.85 billion, a price-to-earnings ratio of 11.64, a P/E/G ratio of 0.70 and a beta of 0.10. The company has a 50 day moving average price of $10.35 and a two-hundred day moving average price of $9.84.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.03. The business had revenue of $881.71 million during the quarter, compared to the consensus estimate of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.09% and a net margin of 41.08%. On average, research analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.78 EPS for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.